vimarsana.com

Latest Breaking News On - Opaleye management inc - Page 1 : vimarsana.com

Applied Therapeutics, Inc. (NASDAQ:APLT) Major Shareholder Sells $631,500.00 in Stock

Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) major shareholder Real Estate Equitie Alexandria sold 150,000 shares of Applied Therapeutics stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $4.21, for a total value of $631,500.00. Following the completion of the transaction, the insider now directly owns […]

Canada
United-states
Leerink-partnrs
Artal-group
Citigroup
Knoll-capital-management
Nasdaq
Opaleye-management-inc
Altitude-crest-partners-inc
Therapeutics-inc
Janus-henderson-group
Royal-bank

Short Interest in Allakos Inc. (NASDAQ:ALLK) Declines By 9.1%

Allakos Inc. (NASDAQ:ALLK – Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 5,080,000 shares, a drop of 9.1% from the April 30th total of 5,590,000 shares. Based on an average daily volume of 528,900 shares, the days-to-cover ratio is […]

United-states
Allakos-inc
Redmile-group
Acadian-asset-management
Blackstone-inc
Opaleye-management-inc
Nasdaq
Get-free-report
Asset-management
Allakos-daily

Harrow, Inc. (NASDAQ:HROW) Short Interest Down 9.5% in May

Harrow, Inc. (NASDAQ:HROW – Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 4,980,000 shares, a decline of 9.5% from the April 30th total of 5,500,000 shares. Based on an average daily volume of 510,400 shares, the […]

Markl-baum
Craig-hallum
Pricet-rowe-associates-inc
Surface-ophthalmics-inc
Pharmaceuticals-inc
Nasdaq
Opaleye-management-inc
Harrow-inc
Vanguard-group-inc
Harrow-health-inc
Eton-pharmaceuticals-inc
Get-free-report

iBio (NYSE:IBIO) Earns Buy Rating from Analysts at Chardan Capital

Chardan Capital assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 price target on the stock. Separately, StockNews.com started coverage on iBio in a research note on Saturday, April 20th. They issued a sell rating for the […]

United-states
Bio-inc
Ikarian-capital
Opaleye-management-inc
Chardan-capital
Free-report
Bio-trading-down
Get-free-report
Opaleye-management
Bio-daily

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $15,992.75 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Masaru Matsuda sold 1,775 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $9.01, for a total transaction of $15,992.75. Following the transaction, the insider now directly owns 188,508 shares in the […]

Masaru-matsuda
Arcutis-biotherapeutics
Franklin-resources-inc
Nasdaq
Goldman-sachs-group
Farallon-capital-management
Arcutis-biotherapeutics-inc
Jennison-associates
Opaleye-management-inc
Securities-exchange-commission
Arcutis-biotherapeutics-company-profile
Needham-company

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.